CoreCap Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History

CoreCap Advisors’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$141K	Hold	280	–	–	﹤0.01%	976
2026 Q2	$150K	Buy	280 +3	+1%	+$1.54K	﹤0.01%	961
2026 Q1	$145K	Buy	277 +195	+238%	+$93.2K	﹤0.01%	899
2025 Q4	$47.8K	Buy	82 +14	+21%	+$7.15K	﹤0.01%	1361
2025 Q3	$31.2K	Hold	68	–	–	﹤0.01%	1502
2025 Q2	$20.6K	Hold	68	–	–	﹤0.01%	1606
2025 Q1	$22.5K	Hold	68	–	–	﹤0.01%	1485
2024 Q4	$21K	Hold	68	–	–	﹤0.01%	1519
2024 Q3	$14.4K	Buy	+68	New	+$17.4K	﹤0.01%	1675
2024 Q2	–	Sell	-68	Closed	-$18.2K	–	2209
2024 Q1	$18.2K	Buy	+68	New	+$16K	﹤0.01%	1524
2022 Q4	$19.7K	Buy	+68	New	+$6.65K	﹤0.01%	1312
2022 Q3	–	Sell	-68	Closed	-$5K	–	1443
2022 Q2	$5K	Buy	+68	New	+$5K	﹤0.01%	1678
2022 Q1	–	Sell	-68	Closed	-$6K	–	1441
2021 Q4	$6K	Buy	+68	New	+$5.59K	﹤0.01%	1705

Other funds holding MDGL

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Bourgeon Capital Management Darien, Connecticut $696M AUM 39.92% 1-Year Est. Return

Shikiar Asset Management New York $398M AUM 33.64% 1-Year Est. Return

Stanley-Laman Group Berwyn, Pennsylvania $915M AUM 50.26% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $13.1B AUM 35.37% 1-Year Est. Return

AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

Newbridge Financial Services Group Boca Raton, Florida $868M AUM 42.47% 1-Year Est. Return

SGH

Sivik Global Healthcare Greenwich, Connecticut $175M AUM 28.78% 1-Year Est. Return

CoreCap Advisors's MDGL Position: Q3 2026 in Review

CoreCap Advisors held its Madrigal Pharmaceuticals (MDGL) position steady in Q3 2026 at 280 shares worth $141K. The position accounts for ﹤0.01% of the portfolio, ranked #976.

CoreCap Advisors first reported a position in MDGL in Q4 2021 and has held it in 13 quarters since. The position peaked at $150K in Q2 2026. 58 funds tracked by Wall St. Rank hold MDGL as of Q3 2026.

CoreCap Advisors held 280 shares of Madrigal Pharmaceuticals worth $141K as of Q3 2026.
CoreCap Advisors left its Madrigal Pharmaceuticals share count unchanged in Q3 2026.
Madrigal Pharmaceuticals made up ﹤0.01% of CoreCap Advisors's portfolio in Q3 2026, its #976 holding.
CoreCap Advisors first reported a position in Madrigal Pharmaceuticals in Q4 2021 and has held it in 13 quarters since.
CoreCap Advisors's Madrigal Pharmaceuticals position peaked at $150K in Q2 2026.
58 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2026.

Based on CoreCap Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.